stella
beta
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO) — Stella
Recruiting
Back to MECP2 Duplication Syndrome trials
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(1 site)
China
Peking University First Hospital, Beijing, Beijing Municipality
View full record on ClinicalTrials.gov